Forian (FORA)
Market Price (3/11/2026): $2.08 | Market Cap: $64.7 MilSector: Health Care | Industry: Health Care Technology
Forian (FORA)
Market Price (3/11/2026): $2.08Market Cap: $64.7 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -44% | Weak multi-year price returns2Y Excs Rtn is -63%, 3Y Excs Rtn is -120% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -11% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 37% | Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 46x | |
| Megatrend and thematic driversMegatrends include Cloud Computing, and Digital Health & Telemedicine. Themes include Software as a Service (SaaS), Health Data Analytics, Show more. | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15% | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.5% | ||
| Key risksFORA key risks include [1] its persistent unprofitability with an uncertain path to positive earnings and [2] a significant revenue dependence on the successful renewal of key customer contracts, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -44% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 37% |
| Megatrend and thematic driversMegatrends include Cloud Computing, and Digital Health & Telemedicine. Themes include Software as a Service (SaaS), Health Data Analytics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -63%, 3Y Excs Rtn is -120% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -11% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 46x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.5% |
| Key risksFORA key risks include [1] its persistent unprofitability with an uncertain path to positive earnings and [2] a significant revenue dependence on the successful renewal of key customer contracts, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Mixed Financial Performance and Outlook Led to Investor Caution.
Forian reported Q3 2025 revenue of $7.76 million, a substantial 66% increase year-over-year, and a narrowed net loss to $0.151 million ($0.00 per share) from $0.205 million ($0.01 per share) in the prior year. Despite these positive top-line and profitability improvements, the company's Q3 2025 operating margin remained negative at -6.0%, following an annual operating margin of -34.7% for FY2024. This mixed financial picture, combined with Q4 2025 consensus EPS forecasts remaining negative at -$0.02, suggests that while revenue growth is strong, sustained profitability is still a concern for investors. After the Q3 2025 earnings announcement on November 14, 2025, the stock closed down 0.47%.
2. Lack of Strong Analyst Conviction and Limited Upside Potential.
Analyst sentiment for Forian has been largely neutral, with Roth MKM downgrading the stock from Buy to Neutral on November 18, 2025, and setting a price target of $2.1. The median price target from analysts is $2.10, which implies only a 1.0% upside from the stock's trading price of $2.08 as of late February 2026. In the last three months, FORA has received 17 "Hold" ratings against only 1 "Buy" rating, indicating a lack of strong catalysts identified by the analyst community that would drive significant price appreciation.
Show more
Stock Movement Drivers
Fundamental Drivers
The -1.0% change in FORA stock from 11/30/2025 to 3/10/2026 was primarily driven by a -1.0% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3102026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.10 | 2.08 | -1.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 28 | 28 | 0.0% |
| P/S Multiple | 2.3 | 2.3 | -1.0% |
| Shares Outstanding (Mil) | 31 | 31 | 0.0% |
| Cumulative Contribution | -1.0% |
Market Drivers
11/30/2025 to 3/10/2026| Return | Correlation | |
|---|---|---|
| FORA | -1.0% | |
| Market (SPY) | -0.9% | -7.8% |
| Sector (XLV) | -2.9% | -5.7% |
Fundamental Drivers
The 5.6% change in FORA stock from 8/31/2025 to 3/10/2026 was primarily driven by a 12.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312025 | 3102026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.97 | 2.08 | 5.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 25 | 28 | 12.3% |
| P/S Multiple | 2.5 | 2.3 | -6.3% |
| Shares Outstanding (Mil) | 31 | 31 | 0.4% |
| Cumulative Contribution | 5.6% |
Market Drivers
8/31/2025 to 3/10/2026| Return | Correlation | |
|---|---|---|
| FORA | 5.6% | |
| Market (SPY) | 5.3% | 15.6% |
| Sector (XLV) | 11.9% | -7.2% |
Fundamental Drivers
The -1.4% change in FORA stock from 2/28/2025 to 3/10/2026 was primarily driven by a -28.3% change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 3102026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.11 | 2.08 | -1.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 20 | 28 | 37.5% |
| P/S Multiple | 3.2 | 2.3 | -28.3% |
| Shares Outstanding (Mil) | 31 | 31 | 0.0% |
| Cumulative Contribution | -1.4% |
Market Drivers
2/28/2025 to 3/10/2026| Return | Correlation | |
|---|---|---|
| FORA | -1.4% | |
| Market (SPY) | 15.0% | 13.1% |
| Sector (XLV) | 4.2% | 5.6% |
Fundamental Drivers
The -59.8% change in FORA stock from 2/28/2023 to 3/10/2026 was primarily driven by a -76.2% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3102026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.17 | 2.08 | -59.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 17 | 28 | 63.4% |
| P/S Multiple | 9.6 | 2.3 | -76.2% |
| Shares Outstanding (Mil) | 32 | 31 | 3.2% |
| Cumulative Contribution | -59.8% |
Market Drivers
2/28/2023 to 3/10/2026| Return | Correlation | |
|---|---|---|
| FORA | -59.8% | |
| Market (SPY) | 77.3% | 10.1% |
| Sector (XLV) | 26.0% | 8.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| FORA Return | -61% | -70% | 7% | -30% | 3% | -1% | -91% |
| Peers Return | -2% | -48% | 4% | -26% | -19% | -26% | -76% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| FORA Win Rate | 40% | 42% | 58% | 33% | 50% | 33% | |
| Peers Win Rate | 47% | 35% | 48% | 40% | 42% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| FORA Max Drawdown | -66% | -76% | -22% | -32% | -15% | -2% | |
| Peers Max Drawdown | -20% | -58% | -25% | -36% | -34% | -34% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -2% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IQV, VEEV, DH, HCAT, CERT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/10/2026 (YTD)
How Low Can It Go
| Event | FORA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -90.7% | -25.4% |
| % Gain to Breakeven | 980.2% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to IQV, VEEV, DH, HCAT, CERT
In The Past
Forian's stock fell -90.7% during the 2022 Inflation Shock from a high on 3/3/2021. A -90.7% loss requires a 980.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Forian (FORA)
AI Analysis | Feedback
Here are 1-3 brief analogies for Forian (FORA):
- Nielsen for the cannabis industry.
- A specialized IQVIA for the cannabis and pharmaceutical sectors.
AI Analysis | Feedback
- Real-World Data Services: Forian provides comprehensive and proprietary datasets collected from various sources within the cannabis and life sciences industries to inform strategic planning and market intelligence.
- Advanced Analytics Solutions: These solutions offer sophisticated analytical tools and capabilities to derive actionable insights from complex data, helping clients understand market trends, evaluate performance, and optimize strategies.
- Cloud-Based Software Platforms (SaaS): Forian offers integrated software-as-a-service platforms that enable data visualization, operational management, and regulatory compliance reporting for businesses in regulated markets.
AI Analysis | Feedback
Forian Inc. (FORA) primarily sells its data, analytics, and software solutions to other businesses (B2B) rather than directly to individuals.
While Forian's financial filings (such as their 10-K) indicate that they derive a significant portion of their revenue from a limited number of major customers (with their largest customer accounting for approximately 10.3% of total revenue in 2023), the company does not publicly disclose the specific names of these individual customer companies. Therefore, specific names of major customers cannot be provided.
Based on their public statements and offerings, Forian serves various types of organizations within the following industries:
- Cannabis Operators: This includes cultivators, processors, dispensaries, manufacturers, retailers, and multi-state operators within the regulated cannabis industry who utilize Forian's data, market intelligence, and compliance tools.
- Healthcare Companies: This broad category encompasses pharmaceutical companies, biotechnology firms, and medical device manufacturers that leverage Forian's analytics and data solutions for market understanding and strategic decision-making.
- Healthcare Providers and Life Sciences Organizations: Including hospitals, clinics, research institutions, and other entities within the broader healthcare and life sciences sectors that benefit from Forian's data insights for patient engagement, treatment optimization, and operational efficiency.
AI Analysis | Feedback
- Amazon.com, Inc. (AMZN)
AI Analysis | Feedback
Max Wygod CEO & Executive ChairMax Wygod is the CEO and Executive Chair of Forian, Inc. He co-founded Forian with Adam Dublin and also co-founded Medical Outcomes Research Analytics, LLC (MOR), which is now an operating subsidiary of Forian. Wygod has a background in investing, acquiring, and divesting public and private growth companies at the intersection of healthcare and information technology. He previously worked at WebMD and has co-invested in several ventures with Adam Dublin. His family has a notable history in managing and selling companies, with his father, Marty Wygod, leading seven public companies, including the sale of WebMD to a KKR portfolio company for $2.8 billion. In August 2025, Max Wygod led a consortium, which includes Adam Dublin, in an unsolicited proposal to take Forian private.
Mike Vesey Chief Financial OfficerMike Vesey serves as the Chief Financial Officer for Forian, a position he assumed in September 2021. He brings over 25 years of experience in financial, transactional, SEC reporting, and accounting roles in both public and private technology companies. Prior to joining Forian, Vesey was the CFO of Wayside Technology Group, Inc. for five years, where he oversaw multiple acquisitions that facilitated the company's transition to a cloud marketplace. Before Wayside, he spent nine years at Majesco Entertainment Company, advancing from Chief Accounting Officer to Chief Financial Officer.
Adam Dublin Co-founder & Chief Strategy OfficerAdam Dublin is a Co-founder and Chief Strategy Officer of Forian. He co-founded Forian (Inc. in 2020) and Medical Outcomes Research Analytics, LLC (MOR in 2019) with Max Wygod. Dublin is also the founder of Health Market Science, Inc. (1999), a supplier of healthcare provider data and solutions. His executive experience includes roles such as Vice President-Strategy & Corporate Development at IQVIA, Inc., Senior Vice President-Corporate Key Accounts at NDCHealth Corp., Senior Vice President-Strategy & Analytics at WebMD Health Corp., and Chief Strategy Officer at SDI Health LLC. He has frequently co-invested in ventures with Max Wygod.
Edward Spaniel, Jr. Executive Vice President, General Counsel and SecretaryEdward Spaniel, Jr. holds the titles of Executive Vice President, General Counsel, and Secretary at Forian. He joined Forian with previous experience at IQVIA, Inc.
AI Analysis | Feedback
Forian (FORA) faces several key risks to its business, primarily related to its financial performance, revenue predictability, and the highly competitive market in which it operates.
-
Unprofitability and Path to Profitability
Forian is currently unprofitable and is not projected to achieve profitability within the next three years. The company's adjusted EBITDA margin for the full year 2025 is uncertain, with projections ranging from a negative $1 million to a positive $1 million. High operating expenses continue to consume a significant portion of its revenue, posing a challenge to achieving sustained profitability.
-
Dependence on Contract Renewals and Mixed Spending Environment
A significant portion of Forian's anticipated revenue, particularly in the latter half of 2025, is contingent upon the successful renewal of contracts, especially annual licenses acquired through the Kyber acquisition. Furthermore, the company navigates a "mixed spending environment" within its healthcare and financial services markets, where pharmaceutical companies exhibit caution due to geopolitical and macroeconomic uncertainties. This reliance on renewals and the cautious market sentiment introduce an execution risk regarding the company's ability to maintain and grow its revenue.
-
Highly Competitive and Crowded Market
Forian operates within a highly competitive healthcare Software as a Service (SaaS) sector, facing competition from numerous active players, including larger entities like Epic and Cerner, which are expanding their analytics offerings. Despite the strategic advantage gained from the Kyber acquisition, providing access to claims data, Forian's market share remains relatively small in this crowded landscape.
AI Analysis | Feedback
The potential entry of larger, diversified data and technology companies into the cannabis analytics market, particularly spurred by progress towards federal cannabis legalization or decriminalization in the United States. These companies could leverage superior financial resources, existing technological infrastructure, and broader market reach to offer more comprehensive or lower-cost solutions, directly competing with and potentially marginalizing specialized providers like Forian.
AI Analysis | Feedback
Forian Inc. (NASDAQ: FORA) primarily offers innovative software solutions, proprietary data, and predictive analytics across two main sectors: the healthcare and life sciences industries, and the cannabis industry. The addressable markets for Forian's main products and services are as follows: * Life Science Analytics Market: The global life science analytics market was valued at approximately USD 12.71 billion in 2024 and is projected to grow to USD 27.75 billion by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 10.5% from 2025 to 2032. North America is a dominant region in this market, holding a 42.8% share in 2024, with its market valued at USD 5.44 billion in the same year. Another source estimates the global market at USD 10.55 billion in 2024, projected to reach USD 16.33 billion by 2030, with a CAGR of 7.50% from 2025 to 2030. The North American life science analytics market, which the U.S. leads, accounted for 49.86% of the global market in 2024. * Cannabis Data and Analytics Market: While Forian is a significant provider of cannabis industry tracking software (BioTrackTHC) and marijuana analytics software (Cannalytics) across the U.S., specific addressable market size figures for *cannabis data and analytics* as a distinct segment are not readily available in the provided search results. The search results indicate Forian's operations in this sector across various U.S. states, monitoring sales, growth, and manufacturing, and working with a range of cannabis clients. However, a quantified market size for this specific data and analytics segment was not found. Therefore, the addressable market for Forian's cannabis data and analytics products cannot be specifically sized based on the provided information, and is returned as null.AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Forian (FORA)
Over the next two to three years, Forian (FORA) is anticipated to drive revenue growth through several key strategies:
- Integration and Expansion of Kyber Data Science: The acquisition of Kyber Data Science in late October 2024 has already proven to be a significant revenue contributor, accounting for approximately $1.9 million or 39% of Forian's Q2 2025 revenue. Forian plans to further enhance Kyber's healthcare-focused software-as-a-service (SaaS) analytics by integrating it with the Forian Data Factory and extending its advanced analytical capabilities into new total addressable markets (TAMs). This acquisition is also expected to bolster recurring, one-year contracts.
- Organic Growth in Life Sciences Data Business: Forian continues to experience organic growth within its core life sciences data business, driven by new pharmaceutical projects and renewals of existing analytical contracts. The company's proprietary "data factory" platform plays a crucial role in processing extensive and diverse data assets to provide real-world evidence and analytics to clients.
- Expansion of Data Capabilities and Advanced Analytics: Forian is actively investing in expanding its data capabilities and integrating advanced analytics. This includes efforts to deliver enhanced information products, particularly in the areas of health economics and outcomes research for life-saving therapies.
- Strategic Acquisitions: The company has expressed a continued commitment to pursuing strategic, value-enhancing acquisitions. These acquisitions are aimed at strengthening Forian's financial position, improving its capital markets profile, expanding its reach with pharmaceutical clients, and accelerating the commercialization of innovative offerings.
- Strong Contract Renewals and New Business Development: Management has indicated a high degree of confidence in future performance, attributing it to a robust pipeline of contract renewals and new business opportunities. The focus on securing new contracts and executing renewals for their data and software solutions is expected to be a consistent driver of revenue.
AI Analysis | Feedback
Share Repurchases
- Forian repurchased an aggregate of 1,604,676 shares of common stock in a privately negotiated transaction for approximately $3.45 million on October 3, 2023.
Share Issuance
- Forian's stockholders approved an amendment to increase the number of shares available under its 2020 Equity Incentive Plan by 4 million shares, totaling 10.4 million shares for issuance, on June 11, 2025. This aims to attract and retain talent through equity compensation.
- Approximately 32 million shares of Forian common stock were outstanding on a fully diluted basis when the company began trading on The Nasdaq Stock Market LLC on March 3, 2021, following the combination of Helix Technologies, Inc. and Medical Outcomes Research Analytics, LLC.
Inbound Investments
- Forian received initial funding in 2020, which included investments from Periphas Capital Healthcare Fund and Novo Holdings A/S.
- In December 2022, the company completed a business combination with a special purpose acquisition company (SPAC), providing additional capital to accelerate product development and global growth.
- An unsolicited, preliminary, non-binding proposal was received on August 2, 2025, from a consortium led by Max Wygod, to acquire the remaining 37% stake in Forian Inc. for $26.4 million.
Outbound Investments
- Forian acquired Kyber Data Science in November 2024 to enhance its data analytics capabilities.
- In 2021, Forian acquired Medical Marijuana Business Daily (MJBizDaily), which expanded its reach and influence within the cannabis industry.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Forian Earnings Notes | 12/16/2025 | |
| Is Forian Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to FORA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.50 |
| Mkt Cap | 0.6 |
| Rev LTM | 367 |
| Op Inc LTM | 9 |
| FCF LTM | 53 |
| FCF 3Y Avg | 53 |
| CFO LTM | 75 |
| CFO 3Y Avg | 69 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.3% |
| Rev Chg 3Y Avg | 6.4% |
| Rev Chg Q | 6.8% |
| QoQ Delta Rev Chg LTM | 1.7% |
| Op Mgn LTM | -1.8% |
| Op Mgn 3Y Avg | -3.1% |
| QoQ Delta Op Mgn LTM | -0.7% |
| CFO/Rev LTM | 19.3% |
| CFO/Rev 3Y Avg | 18.3% |
| FCF/Rev LTM | 14.0% |
| FCF/Rev 3Y Avg | 14.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.6 |
| P/S | 2.0 |
| P/EBIT | 5.9 |
| P/E | -1.0 |
| P/CFO | 11.2 |
| Total Yield | -0.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.5% |
| D/E | 0.4 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -6.5% |
| 3M Rtn | -23.0% |
| 6M Rtn | -34.8% |
| 12M Rtn | -29.7% |
| 3Y Rtn | -52.6% |
| 1M Excs Rtn | -4.3% |
| 3M Excs Rtn | -23.3% |
| 6M Excs Rtn | -38.5% |
| 12M Excs Rtn | -49.6% |
| 3Y Excs Rtn | -127.9% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Providing analytic and information services to the healthcare, life science and financial services | 21 | 16 | |||
| Information and Software | 15 | 1 | |||
| Other | 1 | ||||
| Services | 1 | ||||
| Total | 21 | 16 | 17 | 1 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Providing analytic and information services to the healthcare, life science and financial services | 0 | ||||
| Total | 0 |
Price Behavior
| Market Price | $2.08 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 03/03/2021 | |
| Distance from 52W High | -16.5% | |
| 50 Days | 200 Days | |
| DMA Price | $2.10 | $2.10 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -1.0% | -1.2% |
| 3M | 1YR | |
| Volatility | 17.2% | 56.9% |
| Downside Capture | 16.88 | 42.08 |
| Upside Capture | 0.33 | 38.45 |
| Correlation (SPY) | -6.9% | 12.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.19 | -0.14 | -0.21 | 0.42 | 0.38 | 0.46 |
| Up Beta | -0.06 | -0.56 | -0.53 | 1.26 | 0.38 | 0.46 |
| Down Beta | -0.64 | -0.59 | -0.42 | -0.36 | 0.36 | 0.63 |
| Up Capture | -27% | 14% | -6% | 53% | 25% | 3% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 5 | 16 | 25 | 53 | 106 | 329 |
| Down Capture | 10% | 24% | 0% | 55% | 56% | 82% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 10 | 17 | 25 | 55 | 117 | 368 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FORA | |
|---|---|---|---|---|
| FORA | -5.3% | 57.1% | 0.10 | - |
| Sector ETF (XLV) | 4.0% | 17.5% | 0.07 | 5.7% |
| Equity (SPY) | 18.7% | 19.1% | 0.77 | 13.1% |
| Gold (GLD) | 79.6% | 26.2% | 2.22 | 0.2% |
| Commodities (DBC) | 19.2% | 17.2% | 0.88 | 2.0% |
| Real Estate (VNQ) | 5.3% | 16.4% | 0.14 | 8.1% |
| Bitcoin (BTCUSD) | -20.4% | 45.5% | -0.36 | 2.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FORA | |
|---|---|---|---|---|
| FORA | -38.6% | 75.7% | -0.32 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 10.6% |
| Equity (SPY) | 13.7% | 17.0% | 0.64 | 12.1% |
| Gold (GLD) | 24.5% | 17.2% | 1.16 | 0.1% |
| Commodities (DBC) | 11.6% | 19.0% | 0.50 | 3.1% |
| Real Estate (VNQ) | 5.3% | 18.8% | 0.19 | 10.8% |
| Bitcoin (BTCUSD) | 6.5% | 56.8% | 0.33 | 8.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FORA | |
|---|---|---|---|---|
| FORA | -21.6% | 75.7% | -0.32 | - |
| Sector ETF (XLV) | 10.3% | 16.5% | 0.51 | 10.6% |
| Equity (SPY) | 14.9% | 17.8% | 0.72 | 12.1% |
| Gold (GLD) | 15.1% | 15.6% | 0.81 | 0.1% |
| Commodities (DBC) | 8.9% | 17.6% | 0.42 | 3.1% |
| Real Estate (VNQ) | 5.9% | 20.7% | 0.25 | 10.8% |
| Bitcoin (BTCUSD) | 66.0% | 66.8% | 1.05 | 8.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/14/2025 | 4.2% | 1.9% | 0.0% |
| 8/13/2025 | 1.6% | -0.5% | 18.4% |
| 5/14/2025 | 20.4% | 10.2% | 4.8% |
| 11/13/2024 | -0.5% | 0.5% | 0.0% |
| 8/14/2024 | -2.8% | -2.8% | -7.7% |
| 3/28/2024 | -13.9% | -11.7% | -19.7% |
| 11/9/2023 | 8.3% | 12.5% | 2.1% |
| 8/10/2023 | -1.5% | -0.4% | -11.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 7 | 6 |
| # Negative | 7 | 8 | 9 |
| Median Positive | 4.5% | 10.2% | 3.5% |
| Median Negative | -3.3% | -6.9% | -17.5% |
| Max Positive | 20.4% | 12.8% | 38.4% |
| Max Negative | -13.9% | -15.9% | -44.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/11/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Wygod, Max C | Exec Chairman, CEO & President | Direct | Buy | 2182025 | 2.96 | 880 | 2,605 | 3,933,624 | Form |
| 2 | Wygod, Max C | Exec Chairman, CEO & President | Direct | Buy | 2132025 | 2.67 | 12,320 | 32,933 | 3,540,554 | Form |
| 3 | Wygod, Max C | Exec Chairman, CEO & President | Direct | Buy | 2132025 | 2.52 | 1,747 | 4,402 | 3,342,142 | Form |
| 4 | Wygod, Max C | Exec Chairman, CEO & President | Direct | Buy | 2132025 | 2.73 | 1,800 | 4,914 | 3,625,568 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.